featured
Cardiovascular Toxicity After Sorafenib or Sunitinib Therapy in Older Patients With Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cardiovascular Toxicity After Antiangiogenic Therapy in Persons Older Than 65 Years With Advanced Renal Cell Carcinoma
Cancer 2015 Oct 06;[EPub Ahead of Print], S Jang, C Zheng, HT Tsai, AZ Fu, A Barac, MB Atkins, AN Freedman, L Minasian, AL PotoskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.